Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

Vaccine

Volumn 19, Issue 27, 2001, Pages 3733-3743

  Palker, Thomas J ^a   Monteiro, Juanita M ^a   Martin, Melissa M ^a   Kakareka, Christine ^a   Smith, Judith F ^a   Cook, James C ^a   Joyce, Joseph G ^a   Jansen, Kathrin U ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Human papillomaviruses; Neutralization; Non human primate; Virus like particles

Indexed keywords

ALUMINUM DERIVATIVE; ALUMINUM HYDROXYPHOSPHATE; ANTIBODY; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELL ACTIVITY; CHIMPANZEE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNIZATION SCHEDULE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; PAN TROGLODYTES; PAPILLOMAVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

EID: 0035859293     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00093-7     Document Type: Article

References (68)

1. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers
2. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
3. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
4. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Columbia and Spain
5. Analysis of human papillomavirus types in exophytic condylomata acuminata by hybrid capture and Southern blot techniques
6. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
7. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence and phylogenetic algorithms
8. Detection of genital human papillomavirus infections: Critical review of methods and prevalence studies in relation to cervical cancer
9. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
10. Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
11. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers
12. Heterogeneity of the human papillomavirus group
13. Human papillomavirus in the pathogenesis of anogenital cancer
14. Phylogenetic classification of human papillomaviruses: Correlation with clinical manifestations
15. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
16. Human papillomavirus infection and genital warts: Update on epidemiology and treatment
17. Sexually transmitted diseases quarterly report: Genital warts and genital herpes simplex infection in England and Wales
18. Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention
19. Genital human papillomaviruses-prospects for vaccination
20. Papillomaviruses: Prophylactic vaccine prospects
21. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
22. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
23. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
24. Protection against papillomavirus with a polynucleotide vaccine
25. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
26. Papillomavirus-like particle vaccines for cervical cancer
27. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
28. HPV6b virus like particles are potent immunogens without adjuvant in man
29. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
30. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
31. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles
32. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
33. Chimeric papillomavirus virus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model
34. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
35. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
36. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
37. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination
38. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women
39. Human papillomavirus infections in a group for renal transplant recipients
40. Detection of multiple human papillomavirus types in condylomata acuminata from immunosuppressed patients
41. Recurrent respiratory papillomatosis: Altered CD8+ T-cell subsets and TH1/TH2 cytokine imbalance
42. Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: Correlation of TAP-1 with disease
43. The expanding universe of T-cell subsets: Th1, Th2 and more
44. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae
45. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae
46. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae
47. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae
48. Monoclonal antibody mediated neutralization of infectious human papillomavirus type 11
49. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
50. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
51. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1
52. Neutralization of human papillomavirus (HPV) pseudovirions: A novel and efficient approach to detect and characterize HPV neutralizing antibodies
53. Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus
54. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papilloma type 16 L1
55. Generation of Epstein-Barr (EBV)-immortalized B cell lines
56. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration
57. Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells
58. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV model
59. Morphological transformation in vivo of the human uterine cervix with papillomavirus from condylomata acuminata
60. Genital human papillomaviruses - prospects for vaccination
61. The immunology of animal papillomaviruses
62. Cellular immunity in cutaneous and genital HPV infections
63. Immunologic events in regressing genital warts
64. Cellular responses to interferon-γ
65. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes
66. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
67. Rodent models of lymphocyte migration
68. The physiology of lymphocyte migration through the single lymph node in vivo